Yousef Tanas

Dr. Yousef Tanas

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2023 in Clinical Cardiology
Verified
Journal Article
Open access
YDYomna E. Dean
Yomna E. Dean
MSMohamed A. Shebl
Mohamed A. Shebl
SRSamah S. Rouzan
Samah S. Rouzan
BBBdoor Ahmed A Bamousa
Bdoor Ahmed A Bamousa
NTNesreen Elsayed Talat
Nesreen Elsayed Talat
HAHani Aiash
Hani Aiash
Background: Insomnia has been closely associated with cardiovascular disease (CVD) including myocardial infarction (MI). Our study aims to assess the eligibility of insomnia as a potential risk factor for MI.Methods: PubMed, Scopus, and Web of Science were searched using terms; such as “Insomnia” and “MI.” Only observational controlled studies with data on the incidence of MI among insomniacs were included. Revman software version 5.4 was used for the analysis.Results: Our pooled analysis showed a significant association between insomnia and the incidence of MI compared with noninsomniacs (relative risk [RR] = 1.69, 95% confidence interval [CI] = 1.41–2.02, p < .00001). Per sleep duration, we detected the highest association between ≤5 h of sleep, and MI incidence compared to 7−8 h of sleep (RR = 1.56, 95% CI = 1.41–1.73). Disorders of initiating and maintaining sleep were associated with increased MI incidence (RR = 1.13, 95% CI = 1.04–1.23, p = .003). However, subgroup analysis of nonrestorative sleep and daytime dysfunction showed an insignificant association with MI among both groups (RR = 1.06, 95% CI = 0.91–1.23, p = .46). Analysis of age, follow‐up duration, sex, and comorbidities showed a significant association in insomniacs.Conclusion: Insomnia and ≤5 h of sleep are highly associated with increased incidence of MI; an association comparable to that of other MI risk factors and as such, it should be considered as a risk factor for MI and to be incorporated into MI prevention guidelines.

5 February 2025 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
AAAlaa Abdrabou Abouelmagd
Alaa Abdrabou Abouelmagd
AAAmro Mamdouh Abdelrehim
Amro Mamdouh Abdelrehim
MBMohamed Nabih Bashir
Mohamed Nabih Bashir
FAFares Abdelsalam
Fares Abdelsalam
AMAhmed Marey
Ahmed Marey
MBMohamed Mohamed Belal
Mohamed Mohamed Belal
Retatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. PubMed, Scopus, Web of Science, and Cochrane databases were searched from inception until May 2024. Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients. We excluded studies on healthy populations, non-English texts, single-arm studies, animal studies, and abstracts. RevMan software (version 5.4) was used for analysis, with subgroup evaluation by dose (4 mg, 8 mg, 12 mg). Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria. Retatrutide significantly reduced body weight (mean difference [MD]: −14.33%), body mass index (MD: −5.38), waist circumference (MD: −10.51 cm), fasting plasma glucose (MD: −23.51 mg/dL), hemoglobin A1c (MD: −0.91%), and systolic and diastolic blood pressure (MD: −9.88 mm Hg and −3.88 mm Hg, respectively), all with P values < 0.00001. No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24). Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile. However, additional large and long-term trials are required to establish these results.

21 October 2024 in Aesthetic Plastic Surgery
Verified
Journal Article
Open access
PDF file
YTYousef Tanas
Yousef Tanas
JTJulie Tanas
Julie Tanas
Background: Superomedial and inferior pedicles are two commonly used techniques in breast reduction and mastopexy. This systematic review and meta-analysis aims to compare the clinical outcomes associated with these two techniques. Methods: PubMed, Scopus, and Web of Science were searched for relevant studies. We included all studies with data comparing superomedial and inferior pedicles. Statistical analyses were performed using RevMan version 5.4. Results: The search yielded 1075 studies, of which 15 were included in the meta-analysis, encompassing 2633 patients (5123 breasts), with 3491 breasts receiving superomedial pedicles and 1632 breasts receiving inferior pedicles. Superomedial pedicles were associated with significantly shorter operative length (MD = − 24.71, 95% CI = − 37.63 to − 11.79, p = 0.0002), higher BREAST-Q breast satisfaction scores (MD = 10.34, 95% CI = 7.72 to 12.96, p < 0.00001), lower infection rates (RR = 0.46, 95% CI = 0.24 to 0.86, p = 0.02), higher incidence of seroma (RR = 3.00, 95% CI = 1.15 to 7.79, p = 0.02), and higher incidence of decreased nipple–areola complex (NAC) sensation (RR = 1.50, 95% CI = 1.12 to 2.01, p = 0.006). No significant differences were observed in asymmetry, fat necrosis, NAC loss, and hematoma. Conclusion: Superomedial pedicles demonstrated higher incidences of decreased NAC sensation and seroma formation, lower incidence of infection, shorter operative length, and higher BREAST-Q breast satisfaction scores compared to inferior pedicles. Further research is needed to confirm these findings and explore the long-term aesthetic outcomes associated with both techniques. Level of Evidence III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

1 October 2024 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
YTYousef Tanas
Yousef Tanas
JTJulie Tanas
Julie Tanas
SSSarya Swed
Sarya Swed
ASAldona J. Spiegel
Aldona J. Spiegel
Background: Deep inferior epigastric perforator (DIEP) flaps and latissimus dorsi (LD) flaps are two widely used breast reconstruction techniques, each with distinct advantages and limitations. This meta-analysis aims to compare patient satisfaction and incidence of complications between these two techniques to inform clinical decision-making. Methods: PubMed, Scopus, and Web of Science were searched for relevant studies. We included studies with data comparing DIEP and LD flaps, BREAST-Q patient satisfaction, and complications. Statistical analyses were performed using RevMan 5.4. Results: The search yielded 788 studies, of which 13 were included in the meta-analysis. A total of 2128 patients were analyzed, with 1378 undergoing DIEP flap reconstruction and 750 receiving LD flap reconstruction. The analysis showed greater improvement with DIEP flaps in breast satisfaction [mean difference (MD) = 9.48, 95% confidence interval (CI) = 6.90–12.05, P < 0.00001], physical well-being (MD = 5.95, 95% CI = 2.98–8.92, P < 0.0001), and satisfaction with outcome (MD = 9.36, 95% CI = 3.01–15.71, P = 0.004). Nonetheless, DIEP flaps had higher rates of skin flap necrosis [risk ratio (RR) = 4.27, 95% CI = 2.44 to 7.46, P < 0.00001], wound dehiscence (RR = 5.12, 95% CI = 2.53–10.35, P < 0.00001), and reoperation (RR = 2.24, 95% CI = 1.58 -3.16, P < 0.00001) but lower seroma rates (RR = 0.27, 95% CI = 0.10–0.74, P = 0.01). Conclusions: DIEP flap reconstruction offers superior patient satisfaction compared with LD flap reconstruction, despite a higher incidence of certain complications.

8 January 2025 in Aesthetic Surgery Journal Open Forum
Verified
Journal Article
Open access
YTYousef Tanas
Yousef Tanas
GVGioacchino De Sario Velasquez
Gioacchino De Sario Velasquez
JTJulie Tanas
Julie Tanas
GGGrace Gasper
Grace Gasper
STShadi Tanas
Shadi Tanas
MKMurad Karadsheh
Murad Karadsheh
Background: AlloDerm (LifeCell, Branchburg, NJ) and DermACELL (LifeNet Health, Virginia Beach, VA) are 2 commonly used acellular dermal matrices (ADMs) in aesthetic and reconstructive breast surgery. Objectives: In this head-to-head meta-analysis, the authors aim to compare the clinical outcomes, including complication rates and BREAST-Q patient satisfaction, associated with AlloDerm and DermACELL. Methods: PubMed, Scopus, and Web of Science were searched for relevant studies in April 2024 and again in April 2025. The authors included all studies with data comparing AlloDerm and DermACELL. Statistical analyses were performed using RevMan 5.4. Heterogeneity was assessed using I2 statistics. A random-effects model was applied in case of significant heterogeneity followed by sensitivity analysis. Results: The search yielded 1006 studies, of which 14 were included in the meta-analysis. A total of 1872 patients (2940 breasts) were analyzed, with 1724 breasts receiving AlloDerm and 1433 breasts receiving DermACELL. The analysis revealed that AlloDerm was associated with a slightly higher incidence of seroma formation (risk ratio = 1.49, 95% CI, 1.14-1.95, P = .003) compared with DermACELL, which may be because of surgical technique rather than ADM. No significant differences were observed in the rates of all other complications and BREAST-Q outcomes. Further, there was no statistically significant difference in the rate of red breast syndrome after sensitivity analysis. Conclusions: DermACELL demonstrated a slightly lower incidence of seroma formation compared with AlloDerm. Further randomized trials are needed to confirm these results and explore the long-term outcomes associated with both ADMs. Level of Evidence: 3 (Therapeutic):

18 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GVGioacchino D De Sario Velasquez
Gioacchino D De Sario Velasquez
YTYousef Tanas
Yousef Tanas
FTFrancesca Taraballi
Francesca Taraballi
THTany Lynn Herzog
Tany Lynn Herzog
ASAldona J. Spiegel
Aldona J. Spiegel
This review investigates the intersection of tissue engineering and 3D printing technologies in the realm of breast reconstruction, underscoring the transformative potential these approaches offer for enhancing post-mastectomy outcomes. It encompasses a detailed examination of current methodologies, focusing on the creation of biocompatible, bioabsorbable scaffolds that adeptly mimic the extracellular matrix to promote tissue integration and regeneration. A significant portion of the analysis draws from a search conducted on PubMed, which aimed to collate relevant preclinical and clinical studies in this domain. This search underscored the nascent stage of many applications, highlighting a critical need for more comprehensive preclinical trials to validate the efficacy and safety of these innovative solutions. Our search revealed that many studies have studied alternatives for breast reconstruction using tissue engineering; with a significant proportion of these modalities focusing on using flaps inside 3D-printed chambers. Moreover, although some studies have shown significant adipose tissue growth, their results still do not approximate breast dimensions. Specifically, the review identifies a limited range of polymers that have been explored in preclinical and clinical studies for breast reconstruction, including tissue-engineering chambers and scaffolds for the reconstruction of the breast mound made of poly-lactic acid, poly-glycolic acid, poly-lactic-co-glycolic acid, poly-4-hydroxybutyrate, polycarbonate, and polycaprolactone. For nipple reconstruction, two studies assessed scaffolds made of poly-4-hydroxybutyrate and poly-lactic acid. The review highlights the utilization of bioabsorbable materials in these devices, indicating the potential for performing one-stage surgeries. Moreover, it elaborates on the biomechanical properties of these materials, aligning them with the specific goals of breast reconstruction. The review acknowledges the complexity of navigating regulatory landscapes, suggesting that overcoming these obstacles is essential for clinical translation. Despite these challenges, the convergence of 3D printing and tissue engineering is presented as a paradigm shift in breast reconstruction, offering the potential to significantly enhance aesthetic and functional outcomes, minimize post-surgical complications, and improve patients' quality of life.